Highly efficient suicide gene expression in hepatocellular carcinoma cells by epstein-barr virus-based plasmid vectors combined with polyamidoamine dendrimer.
The present study was aimed at devising an efficient nonviral strategy for suicide gene therapy of hepatocellular carcinoma (HCC). To improve the efficiency of DNA delivery and expression, we applied Epstein-Barr virus (EBV)-based plasmid vectors instead of conventional plasmid vectors and combined them with cationic liposome (EBV/lipoplex) or polyamidoamine dendrimer (PAAD) (EBV/polyplex). When the beta-galactosidase gene was transferred to HuH7, PLC/PRF/5, or HLE cells, < or =50-fold higher beta-galactosidase activities were demonstrated in the cells transfected with EBV vector compared with those transfected with conventional plasmid vectors. PAAD-mediated transfection of HCC with pSES.Tk (an EBV-based vector carrying the herpes simplex virus-1 thymidine kinase gene) resulted in a marked reduction in viable cell number by the addition of ganciclovir (GCV). The HCC cells transfected with pSES.Tk/PAAD showed 100- to 1000-fold higher susceptibilities to GCV than those transfected with pS.Tk (a conventional plasmid vector carrying herpes simplex virus-1 thymidine kinase gene)/PAAD. The pSES.Tk-transfected HCC cells were effectively killed by day 9 in culture with a clinically feasible concentration of GCV (25 microM), whereas the pS.Tk-transfected cells survived the culture. These results demonstrate highly efficient suicide gene transfer into various HCC cells by EBV-based plasmid vectors in vitro, suggesting the possible application of this nonviral vector system to gene therapy of HCC.
Harada
Y
Y
Third Department of Internal Medicine, Kyoto Prefectural University of Medicine, Kamikyo, Japan.
Iwai
M
M
Tanaka
S
S
Okanoue
T
T
Kashima
K
K
Maruyama-Tabata
H
H
Hirai
H
H
Satoh
E
E
Imanishi
J
J
Mazda
O
O
D000970:Antineoplastic Agents / Q000378:metabolism / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000628:therapy*; D015774:Ganciclovir / Q000378:metabolism / Q000627:therapeutic use; D015870:Gene Expression; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors; D018259:Herpesvirus 1, Human / Q000201:enzymology; D004854:Herpesvirus 4, Human / Q000235:genetics*; D006801:Humans; D008081:Liposomes; D008113:Liver Neoplasms / Q000473:pathology / Q000628:therapy*; D011355:Prodrugs / Q000378:metabolism / Q000494:pharmacology; D013937:Thymidine Kinase / Q000235:genetics* / Q000378:metabolism; D014162:Transfection / Q000379:methods; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D008081:Liposomes; D011355:Prodrugs; D013937:Thymidine Kinase; D015774:Ganciclovir